Loading...
Loading...
SEEL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 17.4M |
| Operating I/L | -17.4M |
| Other Income/Expense | -2.2M |
| Interest Income | 0.0M |
| Pretax | -19.6M |
| Income Tax Expense | 2.2M |
| Net Income/Loss | -21.8M |
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system, respiratory, and other disorders. The company's lead programs include SLS-002, an intranasal racemic ketamine for treating acute suicidal ideation in patients with major depressive disorders; SLS-005, a protein stabilizer for amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for Parkinson's disease. Additionally, Seelos has preclinical programs targeting PD, chronic inflammation in asthma, narcolepsy, and post-operative pain management.
